Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camlipixant PK and Bioavailability Study in Healthy Adults
NCT07684586Phase 1Withdrawn
- Sponsor
- GSK
- Start
- Jul 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of camlipixant in refractory chronic cough (RCC) (2 arms), sponsored by GSK. Primary endpoints: Maximum Observed Concentration, Area Under the Curve from Zero up to 24 hours and 1 more. Planned start Jul 2026; status: withdrawn.
02
Drugs
camlipixant
03
Conditions
refractory chronic cough (RCC)
Beyond the preview
Go deeper on NCT07684586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07684586.